May 8, 2026 — CARsgen Therapeutics announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for satri-cel, the world's first CAR-T cell therapy filed for approval to treat a solid tumor. The target is Claudin18.2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy.
Satri-cel has received Breakthrough Therapy Designation and Priority Review status from the NMPA, which could speed up the approval timeline. If approved — expected by late 2026 — it would be a first: CAR-T therapy has only ever worked against blood cancers; this would be the first approved use against a solid tumor in any major regulatory market.
Separately, the NMPA approved three new CAR-T products between March 2025 and March 2026, bringing China's total to five NMPA-approved CAR-T therapies. That pace now matches or exceeds FDA CAR-T approvals in the same period.
CAR-T (Chimeric Antigen Receptor T-cell) therapy works by collecting a patient's own T-cells, genetically engineering them to recognize and attack cancer cells, then infusing them back into the patient. For certain blood cancers — including specific lymphomas, leukemias, and multiple myeloma — CAR-T has achieved complete remission rates of 50–80% in patients who had exhausted all other options.
In the United States, a single CAR-T treatment runs $373,000–$475,000 for the therapy alone, not including hospitalization, monitoring, and supportive care, which can push total costs above $1 million. Even with insurance, out-of-pocket costs can be financially devastating.
China now has five NMPA-approved CAR-T products as of early 2026:
| Product | Manufacturer | Target | Approved Indication | Approximate Cost (USD) |
|---|---|---|---|---|
| Relma-cel (瑞基奥仑赛) | JW Therapeutics | CD19 | Relapsed/refractory large B-cell lymphoma | $165,000 |
| Axi-cel (阿基仑赛) | Fosun Kite | CD19 | Relapsed/refractory large B-cell lymphoma | $165,000 |
| Equecabtagene Autoleucel | IASO Bio | BCMA | Relapsed/refractory multiple myeloma | $137,000 |
| Zevorcabtagene Autoleucel | Nanjing Legend | BCMA | Relapsed/refractory multiple myeloma | $137,000 |
| Inaticabtagene Autoleucel | Hrain Biotech | CD19 | Relapsed/refractory B-cell ALL | $137,000 |
For comparison, approved US products — Kymriah ($475,000), Yescarta ($373,000), Tecartus ($373,000), Abecma ($419,500), and Carvykti ($465,000) — cost two to three times more than China's equivalents.
China is the world's second-largest hub for CAR-T clinical trials, with hundreds of active trials across the country. For international patients, clinical trials offer several advantages: therapy costs are often reduced to $40,000–$80,000 or sometimes free for the therapy itself, access to next-generation CAR-T products not yet commercially available, and the possibility of treatment for cancer types not yet covered by approved products.
Clinical trials in China cover a range of cancers including B-cell lymphoma and leukemia (CD19 targets), multiple myeloma (BCMA targets), and increasingly solid tumors such as hepatocellular carcinoma, gastric cancer, and lung cancer. The satri-cel gastric cancer NDA is itself a landmark result from this trial activity.
CAR-T therapy is typically considered for patients who meet these criteria:
These Chinese hospitals have the most experience treating international CAR-T patients:
CAR-T therapy requires a longer stay in China compared to other medical tourism procedures — typically 6–8 weeks total:
CAR-T therapy is not a simple or risk-free procedure. Patients and families should understand:
| Factor | United States | China |
|---|---|---|
| Approved CAR-T products | 5 products (Kymriah, Yescarta, Tecartus, Abecma, Carvykti) | 5 NMPA-approved products (+ satri-cel pending) |
| Therapy cost (drug only) | $373,000–$475,000 | $120,000–$170,000 |
| Total estimated cost (incl. hospital, monitoring) | $500,000–$1,000,000+ | $150,000–$220,000 |
| Savings vs. US | — | 60–75% lower |
| Average wait time for manufacturing slot | 2–3 weeks | 2–4 weeks |
| Hospital stay required | 7–21 days (depending on product and risk) | 7–14 days (standard monitoring) |
| International patient support | Available at major cancer centers | Available at designated international hospitals |
| Solid tumor CAR-T access | Clinical trials only (none approved) | Satri-cel NDA accepted May 2026 (gastric cancer) |
CAR-T therapy in China may be the right choice for:
If you are considering CAR-T therapy in China, here is a practical starting path:
| NMPA-approved CAR-T (commercial) | $150,000–$220,000 total |
| CAR-T therapy drug cost | $120,000–$170,000 |
| Hospital stay + monitoring (14 days) | $15,000–$25,000 |
| Physician fees + lab tests | $8,000–$15,000 |
| Translation + patient coordination | $2,000–$5,000 |
| CAR-T via clinical trial | $40,000–$80,000 (therapy free or reduced at many trials) |
| Total with trial (incl. all other costs) | $70,000–$120,000 |
Not sure if CAR-T therapy in China is right for your case? Send us your medical records and our care coordination team will identify your best options — commercial products and relevant clinical trials — within 3–5 business days.
Request a Free Assessment →CAR-T therapy is an intensive treatment with real risks. The most common serious side effect is cytokine release syndrome (CRS), which causes high fever, low blood pressure, and organ stress. Most cases are manageable with medication in a hospital setting. Neurological side effects are also possible. Treatment should only be pursued at experienced centers with appropriate ICU-level support. The hospitals listed in this article have track records treating international CAR-T patients.
For approved blood cancer indications, complete remission rates in clinical trials range from 50–80% depending on the cancer type and prior treatment history. This means the cancer becomes undetectable. However, not all patients respond, and some who do respond eventually relapse. Long-term remission data is still being collected for many products.
Approved CAR-T products have completed Phase 3 trials and been reviewed by the NMPA for safety and efficacy. Clinical trial CAR-T is investigational — it may use newer targets or next-generation designs, but efficacy data is less established. Trial participants may receive therapy at reduced cost or no cost, but there is no guarantee of benefit. We can help you assess which pathway is more appropriate for your specific case.
CARsgen's satri-cel, targeting Claudin18.2-positive gastric cancer, had its NDA accepted by the NMPA in May 2026 — a historic first for solid tumor CAR-T. If approved (expected late 2026), it would be commercially available. Until then, gastric cancer CAR-T is accessible primarily through clinical trials. We can help identify trials currently enrolling international patients with gastric cancer.
The full process — evaluation, leukapheresis, manufacturing wait, pre-conditioning, infusion, and initial monitoring — typically requires 6–8 weeks in China. After discharge, patients can return home but need regular follow-up blood tests and check-ups with a local oncologist. Some hospitals offer remote follow-up coordination.
Most international health insurance plans do not automatically cover treatment at overseas hospitals. Some insurers may reimburse CAR-T treatment abroad on a case-by-case basis, particularly if the treatment is not available in the patient's home country. We recommend contacting your insurer before committing to treatment. Medical financ ing and payment plans may also be available through the treating hospital.